** Shares of gene sequencing equipment maker Illumina ILMN.O fall 4.7% to $117 premarket
** Co, late on Thursday, forecast 2025 revenue largely below Wall Street estimates
** Co expects 2025 revenue between $4.28 bln and $4.40 bln, below analysts' average estimate of $4.39 bln at midpoint, according to data compiled by LSEG
** China, which accounts for about 7% of Illumina's sales, placed co on its "unreliable entity" list earlier this week
** Illumina said its forecast does not reflect any impact from announcement from China
** "The lack of adjusting could mean there's hope they could be removed from the 'unreliable entity list' or that they can't yet quantify it" - Piper Sandler analysts
** Up to last close, stock down ~12% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.